STL Index for: Rituximab
Management of Primary Small-Vessel Vasculitis
Small-vessel vasculitides (SVV) are a group of disorders that occur due to primarily systemic inflammation or as sequelae of an infection, malignancy, or other rheumatic disease.
A Dermatologist’s Guide to Infection Screening Prior to Initiating Immunosuppressive Therapy
In this review, we summarize the most common immunosuppressant medications currently used in dermatology, and provide recommendations for infection screening prior to
initiating treatment.
Rituximab: Uses in Dermatology
Rituximab is an anti-CD20 monoclonal antibody with considerable potential in dermatology due to an increase in off-label indications. Off-label use of rituximab, indications, side-effects, and dosing are some of the topics discussed.
Updates on the Management of Autoimmune Blistering Diseases
Autoimmune blistering diseases are rare, but potentially debilitating characterized by varying degrees of mucosal and cutaneous bullae formation. This article discusses individually tailored treatment, diagnosis, severity, comorbidities, and tolerance for systemic therapy.
Advances in Pemphigus Therapy
The pemphigus variants represent a group of potentially life-threatening autoimmune mucocutaneous blistering diseases. Herein, we focus on the new and emerging therapies in the management of pemphigus.
Rituximab: A B-Cell Depletion Therapy for Dermatologic Disease
Rituximab (Rituxan®, Genentech/ Biogen Idec) is a genetically engineered chimeric murine/human monoclonal antibody directed against CD20. While anecdotal case reports recommend its “off-label” use in dermatology, randomized clinical trials are required to firmly establish the safety and efficacy.
Update on Drugs and Drug News – February 2007
Update on Clindamycin Phosphate 1.2%/ Tretinoin 0.025% Ziana™ Gel, Adalimumab Humira®, Aminolevulinic Acid/ Light Levulan® Kerastick®, Oblimersen Sodium Injection Genasense™, and Epratuzumab LymphoCide™.
